Phase 2 Study of LY2157299 in Patients With Hepatocellular Carcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2018
At a glance
- Drugs Galunisertib (Primary) ; Ramucirumab; Sorafenib
- Indications Liver cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Eli Lilly
- 29 May 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.
- 29 May 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.
- 25 Sep 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Jun 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History